FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs
Gwynn Ison(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), W. David McGuinn(United States Food and Drug Administration), Runyan Jin(Center for Drug Evaluation and Research), Sarah E. Dorff(United States Food and Drug Administration), Amna Ibrahim(Beni-Suef University), Anshu Marathe(Novartis (Switzerland)), Shenghui Tang(United States Food and Drug Administration), Xavier Ysern(Center for Drug Evaluation and Research), Olen Stephens(Center for Drug Evaluation and Research), Joyce Cheng(United States Food and Drug Administration), William F. Pierce(United States Food and Drug Administration), Todd R. Palmby(University of North Carolina at Chapel Hill), Ge Bai(Inner Mongolia Medical University), Geoffrey Kim(United States Food and Drug Administration), Jeannette Dinin(Center for Drug Evaluation and Research), Qi Liu(United States Food and Drug Administration), Yaning Wang(Yangzhou University), Amy E. McKee(United States Food and Drug Administration), Rosane Charlab, Rajeshwari Sridhara(Center for Drug Evaluation and Research), Julia A. Beaver(Center for Drug Evaluation and Research)
Cited by 80
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k